What is the clinical evidence from this study?

Study design: Review. Population: Cardiovascular toxicity of antidepressants. Intervention: Antidepressant medications.

What does this research mean for the field?

Antidepressant medications, including both standard tricyclic agents and newer alternatives, carry distinct cardiovascular risks such that no currently available agent is entirely without cardiovascular liability. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

February 9, 2010Psychopathology

Cardiovascular Toxicity of Antidepressant Medications

View Full Paper

Ask AI

Bookmark

Key result

All antidepressants carry cardiovascular risks including orthostatic hypotension and conduction delay.

Why the study?

What are the cardiovascular toxicities associated with standard and newer antidepressant medications?

Population

Patients receiving antidepressant medications, including those with congestive heart failure or preexisting…

Design

Review

Authors

WJW JacksonColumbia University SRSteven P. RooseCross-Cutting Cardiology AGA H GlassmanNew York Psychoanalytic Society and Institute

Discussion

Member takes

Implication

Patients with HF or conduction delay face orthostatic and proarrhythmic TCA risks; leaves open comparative safety of newer agents in contemporary cardiac cohorts.

Structured PICO

What are the cardiovascular toxicities associated with standard and newer antidepressant medications?

Population

Patients receiving antidepressant medications, including those with congestive heart failure or preexisting conduction delay

Exposure

Antidepressant medications (standard tricyclic agents and newer drugs including mianserin, nomifensine, bupropion, and trazodone)

Outcome

Cardiovascular toxicity (orthostatic hypotension, conduction delay, antiarrhythmic effects, death in overdose)safety

This review highlights that all currently available antidepressant medications carry some cardiovascular risk, necessitating caution especially in patients with heart failure or conduction disease.

Cite This Study

Jackson et al. (2010) conducted a review in Cardiovascular toxicity of antidepressants. Antidepressant medications was evaluated. Antidepressant medications, including tricyclic and newer agents, carry cardiovascular risks such as orthostatic hypotension and conduction delay, with no drug being entirely without risk.

synapsesocial.com/papers/6aa7587237cfa9e88af63d2d https://doi.org/10.1159/000284525

View Full Paper

Ask AI

Bookmark

Implication

Patients with HF or conduction delay face orthostatic and proarrhythmic TCA risks; leaves open comparative safety of newer agents in contemporary cardiac cohorts.

Cardiovascular Toxicity of Antidepressant Medications

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Cardiovascular Toxicity of Antidepressant Medications

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider